QD325 is a potent redox modulator for the Treatment of Pancreatic Ductal Adenocarcinoma. Nascent RNA sequencing following treatments with QD325 revealed induction of stress responses in the nucleus, endoplasmic reticulum, and mitochondria of pancreatic ca
GJ-072 is a Nonsense suppressor. Nonsense suppressors (NonSups) induce “readthrough”, i.e., the selection of near cognate tRNAs at premature termination codons and insertion of the corresponding amino acid into nascent polypeptide.
Z-Hpg is a novel bortac-gj enabled selective probe for labeling of nascent proteomes, thus recording translation, in cell networks connected by gap junctions, leaving unconnected cells not labeled
Erythromycin A N-oxide is a potential impurity found in commercial preparations of erythromycin. Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains. It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l). Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications. Erythromycin A N-oxide is also a precursor in the synthesis of clarithromycin .
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.[1] It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).[2] Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.[3],[4] Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.[5],[6]